RESEARCH GRID / QUESTION BOARD
Tesamorelin: frequently asked questions, answered from the record
Direct answers on mechanism, pharmacokinetics, efficacy, safety, and regulatory status — each quantitative answer cited to its study.
What is tesamorelin?
Tesamorelin is a synthetic 44-amino-acid analogue of growth hormone-releasing hormone, GHRH(1-44), with an N-terminal trans-3-hexenoic acid group that resists DPP-IV cleavage [8]. It stimulates the body's own pulsatile growth hormone and raises IGF-1. It is FDA-approved only for HIV-associated lipodystrophy [5].
What does tesamorelin do?
It amplifies endogenous pulsatile growth-hormone secretion and raises IGF-1, which drives lipolysis preferentially in visceral abdominal fat [1][4]. The pivotal trials showed selective visceral-fat reduction in HIV-associated lipodystrophy — 15.2% over 26 weeks — without significant change in subcutaneous fat or BMI [1].
How does tesamorelin work?
It binds the GHRH receptor on pituitary somatotrophs, activating the Gs/adenylyl-cyclase/cAMP/PKA cascade to stimulate growth-hormone synthesis and pulsatile release; growth hormone then drives hepatic IGF-1 production and lipolysis [4]. Population PK-PD modeling confirmed the secretion is episodic (pulsatile) rather than continuous [7].
How does tesamorelin stimulate growth hormone release?
It binds the GHRH receptor (a Gs-coupled receptor) on pituitary somatotrophs, raising cAMP via adenylyl cyclase and activating PKA and CREB to drive growth-hormone gene transcription and pulsatile granule release [4]. PK-PD modeling confirmed this episodic, burst-like secretion pattern [7].
Does tesamorelin raise IGF-1 levels?
Yes. By stimulating growth hormone, tesamorelin raises hepatic IGF-1: +81.0% in the pivotal HIV trial [1] and +181 ug/L in healthy men [4]. Elevated IGF-1 underlies both its lipolytic effect and its growth-factor safety warnings, which is why active malignancy is a labeled contraindication [15].
Is tesamorelin a growth hormone?
No. It is a GHRH analogue — it signals the pituitary to release the body's own growth hormone rather than supplying exogenous growth hormone [4]. Because it amplifies the natural pulsatile rhythm instead of flooding the system, its metabolic profile differs from recombinant growth hormone [7].
Is tesamorelin a steroid?
No. Tesamorelin is a peptide GHRH analogue — a chain of amino acids — not a steroid. It does not act on steroid receptors. It works upstream of the growth-hormone axis, signaling the pituitary to release the body's own growth hormone, which then raises IGF-1 [4].
What is the half-life of tesamorelin?
Plasma exposure is short. Population PK modeling reported apparent clearance ~1,060 L/h [6]; preclinical studies measured a terminal half-life of roughly 21-45 minutes in dogs [8] and ~26 minutes after subcutaneous dosing [9], while downstream IGF-1 elevation persists across the dosing interval [6].
How long does tesamorelin stay in your system?
The parent peptide clears rapidly from plasma (apparent clearance ~1,060 L/h; terminal half-life ~26-45 minutes in preclinical work) [6][8], but its effect — raised growth hormone and IGF-1 — outlasts the measurable drug, which is why the regimen studied in trials was once daily [6][7].
Does tesamorelin need to be refrigerated?
The approved product is supplied as a lyophilized powder requiring reconstitution; published handling notes specify refrigerated storage and use of the reconstituted solution within a defined window [14]. Research-grade material handling follows laboratory protocols, not a self-administration regimen.
How is tesamorelin reconstituted?
The literature describes reconstitution of a lyophilized (freeze-dried) powder before subcutaneous administration [14]. This is summarized here as a published handling note for context only; this page gives no human-use instructions.
Does tesamorelin reduce belly fat?
In HIV patients with abdominal fat accumulation, tesamorelin 2 mg/day reduced visceral adipose tissue by 15.2% over 26 weeks [1]. It is FDA-approved only for that HIV indication [5]; non-HIV fat loss is off-label and not established by large randomized trials [15].
Does tesamorelin burn belly fat?
Trials show selective reduction of visceral (intra-abdominal) fat, generally without significant change in subcutaneous fat or BMI [1]. The effect is mediated by growth-hormone/IGF-1-driven lipolysis, and a 2026 meta-analysis pooled the visceral-fat reduction at -27.71 cm2 [13].
Does tesamorelin increase the risk of diabetes or affect blood sugar?
In healthy men, neither fasting glucose nor insulin-stimulated glucose uptake changed significantly [4]. Across the 52-week HIV program, changes in glucose parameters were not clinically significant [2], though modest perturbation can occur and monitoring is warranted in people with dysglycemia.
Can tesamorelin reduce liver fat?
Yes, in the studied HIV populations: a JAMA RCT showed a net -2.9% hepatic-lipid reduction [3] and a five-RCT meta-analysis reported -4.28% hepatic fat fraction [13]. Long-term liver-histology effects need further study, and use outside HIV-associated fatty-liver disease remains investigational.
Is tesamorelin a potential treatment for non-alcoholic fatty liver disease?
In HIV cohorts, a 6-month JAMA RCT reduced hepatic fat by a net -2.9% [3], and a 2026 meta-analysis reported a pooled hepatic fat-fraction reduction of -4.28% [13]. Use outside HIV-associated fatty-liver disease remains investigational and off-label [15].
What are the side effects of tesamorelin?
Trials reported injection-site reactions and growth-hormone-class effects; glucose monitoring is advised. The label contraindicates active malignancy, hypersensitivity, and pregnancy [15]. The NIH LiverTox monograph assigns a likelihood score of E — unlikely to cause clinically apparent liver injury [5].
Does tesamorelin cause water retention?
Fluid-related effects are recognized growth-hormone-class effects; tesamorelin stimulates endogenous growth hormone and raises IGF-1, and the label carries growth-factor warnings [15]. Reported trial adverse events were generally mild and dominated by injection-site reactions [5].
Who should avoid tesamorelin?
The FDA label contraindicates use in active malignancy (treatment must be complete and the malignancy inactive), known hypersensitivity to tesamorelin or its excipients, and pregnancy (animal studies showed hydrocephaly in offspring) [15]. These are the labeled contraindications, reported here as fact.
Is tesamorelin FDA approved?
Yes, but narrowly: tesamorelin is FDA-approved (NDA 022505, November 2010) only to reduce excess abdominal fat in HIV-infected adults with lipodystrophy [5]. Every other use — cosmetic, anti-aging, non-HIV fat loss — is off-label and not FDA-approved [15].